Thioredoxin: A novel, independent diagnosis marker in children with autism

International Journal of Developmental Neuroscience

Volumn 40, Issue , 2015, Pages 92-96

  Zhang, Qing biao ^a   Gao, Si ju ^a   Zhao, Hong xiang ^a  

^a LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

Autism spectrum disorders; Chinese; Oxidative stress; Thioredoxin

Indexed keywords

C REACTIVE PROTEIN; THIOREDOXIN; THIOREDOXINS;

ARTICLE; AUTISM; CHILD; CHILDHOOD AUTISM RATING SCALE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; AUTISTIC DISORDER; BLOOD; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; HUMANS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

AUTISTIC DISORDER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; THIOREDOXINS;

EID: 84919765326     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2014.11.007     Document Type: Article

References (32)

1. Al-Gayyar M.M.H., Abdelsaid M.A., Matragoon S., et al. Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity. Br. J. Pharmacol. 2011, 164(1):170-180.
2. APA Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
3. Blumberg S.J., Bramlett M.D., Kogan M.D., et al. Changes in prevalence of parent-reported autism spectrum disorder in school-aged US children: 2007 to 2011-2012. Natl. Health Stat. Rep. 2013, 65(20):1-7.
4. Chauhan A., Chauhan V. Oxidative stress in autism. Pathophysiology 2006, 13:171-181.
5. Chiocchetti A.G., Haslinger D., Boesch M., et al. Protein signatures of oxidative stress response in a patient specific cell line model for autism. Mol. Autism 2014, 5(1):10.
6. Chlebowski C., Green J.A., Barton M.L., et al. Using the childhood autism rating scale to diagnose autism spectrum disorders. J. Autism Dev. Disord. 2010, 40(7):787-799.
7. Depino A.M. Peripheral and central inflammation in autism spectrum disorders. Mol. Cell. Neurosci. 2013, 53:69-76.
8. Essa M.M., Guillemin G.J., Waly M.I., et al. Increased markers of oxidative stress in autistic children of the Sultanate of Oman. Biol. Trace Elem. Res. 2012, 147(1-3):25-27.
9. Griffiths H.R., Bennett S.J., Olofsson P., et al. Thioredoxin as a putative biomarker and candidate target in age-related immune decline. Biochem. Soc. Trans. 2014, 42(4):922-927.
10. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 2006, 97:1634-1658.
11. Hattori I., Takagi Y., Nakamura H., Nozaki K., Bai J., Kondo N., Sugino T., Nishimura M., Hashimoto N., Yodoi J. Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid. Redox Signal. 2004, 6:81-87.
12. James S.J., Cutler P., Melnyk S., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr. 2004, 80(6):1611-1617.
13. Jikimoto T., Nishikubo Y., Koshiba M., et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol. Immunol. 2002, 38(10):765-772.
14. Kwon Y.W., Masutani H., Nakamura H., et al. Redox regulation of cell growth and cell death. Biol. Chem. 2003, 384:991-996.
15. Mostafa G.A., El-Hadidi E.S., Hewedi D.H., et al. Oxidative stress in Egyptian children with autism: relation to autoimmunity. J. Neuroimmunol. 2010, 219(1):114-118.
16. Nakamura H. Thioredoxin and its related molecules: update 2005. Antioxid. Redox Signal. 2005, 7:823-828.
17. Nakamura H., De Rosa S., Roederer M., Anderson M.T., Dubs J.G., Yodoi J., Holmgren A., Herzenberg L.A., Herzenberg L.A. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int. Immunol. 1996, 8:603-611.
18. Nakamura H., Nakamura K., Yodoi J. Redox regulation of cellular activation. Annu. Rev. Immunol. 1997, 15:351-369.
19. Ng F., Berk M., Dean O., et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008, 11(06):851-876.
20. Ozcan M.E., Gulec M., Ozerol E., et al. Antioxidant enzyme activities and oxidative stress in affective disorders. Int. Clin. Psychopharmacol. 2004, 19(2):89-95.
21. Pardo C.A., Vargas D.L., Zimmerman A.W. Immunity, neuroglia and neuroinflammation in autism. Int. Rev. Psychiatry 2005, 17:485-495.
22. Roberts E.M., English P.B., Grether J.K., Windham G.C., Somberg L., Wolff C. Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley. Environ. Health Perspect. 2007, 115:1482-1489.
23. Rose S., Melnyk S., Pavliv O., et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl. Psychiatry 2012, 2(7):e134.
24. Ross M.A. Could oxidative stress be a factor in neurodevelopmental disorders?. Prostaglandins Leukot Essent Fatty Acids 2000, 63(1):61-63.
25. Rossignol D.A., Frye R.E. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol. Psychiatry 2012, 17(4):389-401.
26. Schaefer G.B., Mendelsohn N.J. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Genet. Med. 2008, 10:4-12.
27. Sumida Y., Nakashima T., Yoh T., et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J. Hepatol. 2000, 33(4):616-622.
28. Taniguchi Y., Taniguchi-Ueda Y., Mori K., Yodoi J. A novel promotor sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (TRX) gene. Nucl Acids Res. 1996, 24:2746-2752.
29. Tu W., Yin C., Guo Y., et al. Serum homocysteine concentrations in Chinese children with autism. Clin. Chem. Lab. Med. 2013, 51(2):e19-e22.
30. Zhang X.Y., Chen D.C., Xiu M.H., et al. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr. Res. 2009, 113(2):151-157.
31. Zhang Q., Jiang L., Lu Y.J. Serum brain-derived neurotrophic factor levels in Chinese children with autism spectrum disorders: a pilot study. Int. J. Dev. Neurosci. 2014, 37:65-68.
32. Zoroglu S.S., Armutcu F., Ozen S., et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254(3):143-147.